BioLife Solutions (BLFS) Rating Reiterated by Northland Securities

Northland Securities reiterated their buy rating on shares of BioLife Solutions (NASDAQ:BLFS) in a research note released on Monday, AnalystRatings.com reports. They currently have a $18.00 target price on the medical equipment provider’s stock.

“We continue to believe BioLife is one of the better small-cap plays with a lower risk exposure to the biotech / regen med space. Maintain OP rating.”,” Northland Securities’ analyst wrote.

A number of other research firms have also weighed in on BLFS. ValuEngine upgraded BioLife Solutions from a buy rating to a strong-buy rating in a report on Tuesday, March 19th. BidaskClub upgraded BioLife Solutions from a hold rating to a buy rating in a report on Tuesday, March 19th. Finally, Zacks Investment Research lowered BioLife Solutions from a buy rating to a hold rating in a report on Tuesday, March 12th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company presently has an average rating of Buy and a consensus target price of $18.20.

Shares of NASDAQ BLFS opened at $17.74 on Monday. The company has a quick ratio of 12.99, a current ratio of 14.50 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $319.22 million, a P/E ratio of 126.71 and a beta of 1.53. BioLife Solutions has a 52-week low of $8.50 and a 52-week high of $26.35.

BioLife Solutions (NASDAQ:BLFS) last posted its earnings results on Thursday, May 9th. The medical equipment provider reported $0.03 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.03. The company had revenue of $5.77 million during the quarter, compared to analyst estimates of $5.67 million. BioLife Solutions had a return on equity of 10.32% and a net margin of 17.01%. Analysts anticipate that BioLife Solutions will post 0.13 EPS for the current year.

In other news, VP Todd Berard sold 3,000 shares of the stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $16.67, for a total transaction of $50,010.00. Following the completion of the sale, the vice president now owns 44,074 shares in the company, valued at approximately $734,713.58. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Greef Roderick De sold 10,000 shares of the stock in a transaction on Wednesday, February 20th. The shares were sold at an average price of $17.23, for a total value of $172,300.00. Following the sale, the chief financial officer now owns 24,583 shares of the company’s stock, valued at approximately $423,565.09. The disclosure for this sale can be found here. In the last quarter, insiders have sold 78,429 shares of company stock valued at $1,371,446. Company insiders own 38.50% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the company. FMR LLC acquired a new position in shares of BioLife Solutions in the 1st quarter valued at $2,684,000. Vanguard Group Inc increased its position in shares of BioLife Solutions by 43.1% in the 3rd quarter. Vanguard Group Inc now owns 447,984 shares of the medical equipment provider’s stock valued at $7,839,000 after acquiring an additional 134,869 shares during the period. Vanguard Group Inc. increased its position in shares of BioLife Solutions by 43.1% in the 3rd quarter. Vanguard Group Inc. now owns 447,984 shares of the medical equipment provider’s stock valued at $7,839,000 after acquiring an additional 134,869 shares during the period. BlackRock Inc. increased its position in shares of BioLife Solutions by 199.8% in the 3rd quarter. BlackRock Inc. now owns 153,610 shares of the medical equipment provider’s stock valued at $2,688,000 after acquiring an additional 102,364 shares during the period. Finally, Ranger Investment Management L.P. acquired a new position in shares of BioLife Solutions in the 4th quarter valued at $1,108,000. Hedge funds and other institutional investors own 41.21% of the company’s stock.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced cell damage and death.

Further Reading: Fundamental Analysis – How It Helps Investors

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.